Key points are not available for this paper at this time.
Introduction: We asked if marked OGTT metabolic heterogeneity at screening persists at T1D diagnosis. Methods: Multiple Ab+ TrialNet Pathway to Prevention participants (n=364) who had diagnostic OGTTs ≥1 yr after screening OGTTs were stratified by median fasting glucose x fasting C-peptide (fgxfp; basic metabolic component of C-peptide HOMA-IR). Glucose and C-peptide response curves (shapes from mean OGTT glucose and C-peptide at 30, 60, 90 and 120 min; GCRCs) were derived from OGTTs at baseline and diagnosis. Results: The fgxfp groupmedian (Figure: blue) had much higher baseline AUC C-peptide (p0.001), indicated by the wider shape and rightward location of their GCRC. They subsequently had upward and leftward GCRC movement from baseline to diagnosis vs. mostly upward movement for the group Disclosure E.K. Sims: Consultant; Sanofi. Board Member; American Diabetes Association. Other Relationship; American Diabetes Association, Medscape. Consultant; DRI. L.M. Jacobsen: Advisory Panel; Insulet Corporation. H.M. Ismail: Consultant; Sanofi, Rise Therapeutics. M.J. Redondo: None. B.M. Nathan: None. J. Sosenko: None.
Sims et al. (Fri,) studied this question.